• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by OKYO Pharma Limited

    2/18/26 5:42:07 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OKYO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    OKYO Pharma Ltd

    (Name of Issuer)


    Ordinary Shares, no par value

    (Title of Class of Securities)


    G6724L116

    (CUSIP Number)


    02/17/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G6724L116


    1Names of Reporting Persons

    Point72 Asset Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,058,445.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,058,445.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,058,445.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.9 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    G6724L116


    1Names of Reporting Persons

    Point72 Capital Advisors, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,058,445.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,058,445.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,058,445.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.9 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    G6724L116


    1Names of Reporting Persons

    Steven A. Cohen
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,058,445.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,058,445.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,058,445.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    OKYO Pharma Ltd
    (b)Address of issuer's principal executive offices:

    9th Floor, 107 Cheapside, London EC2V 6DN United Kingdom
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the ordinary shares, no par value ("Ordinary Shares"), of OKYO Pharma Limited held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the Ordinary Shares held by Point72 Associates; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the Ordinary Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc. Cubist Systematic Strategies, LLC is a relying adviser on the Form ADV of Point72 Asset Management and acts as a sub-advisor with respect to a portion of the Ordinary Shares reported herein. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
    (c)Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
    (d)Title of class of securities:

    Ordinary Shares, no par value
    (e)CUSIP No.:

    G6724L116
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 17, 2026. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Ordinary Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Ordinary Shares reported herein.
    (b)Percent of class:

    7.9%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 17, 2026.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 17, 2026.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 17, 2026.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 17, 2026.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Ordinary Shares.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Point72 Asset Management, L.P.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:02/18/2026
     
    Point72 Capital Advisors, Inc.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:02/18/2026
     
    Steven A. Cohen
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:02/18/2026
    Exhibit Information

    Exhibit 99.1: Joint Filing Agreement

    Get the next $OKYO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OKYO

    DatePrice TargetRatingAnalyst
    12/8/2025$5.00Buy
    B. Riley Securities
    More analyst ratings

    $OKYO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

    LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the pricing of an underwritten public offering (the "Offering") of 10,815,000 ordinary shares at an offering price of $1.85 per ordinary share. The Company has granted the underwriter a 30-day option to purchase up to an additional 1,622,250 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to the Company from the Offering, before deducting offering expenses pay

    2/12/26 10:20:03 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Public Offering of Ordinary Shares

    LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it intends to offer to sell its ordinary shares in an underwritten public offering (the "Offering"). All of the ordinary shares are to be sold by the Company. The Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in this Offering at the public offering price, less underwriting discounts and commissions. The Offering is subject to market

    2/12/26 4:01:00 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

    LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it has transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners LLC, a leading healthcare-focused investment bank as the sales agent, replacing its previous ATM facility with B. Riley Securities Inc. This strategic move allows OKYO Pharma to continue accessing the capital markets efficiently through an ATM program, enabling the sale of common shares directly into the market from time to time

    2/11/26 10:09:10 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OKYO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Brancaccio John P bought $25,005 worth of Ordinary Shares (16,670 units at $1.50) (SEC Form 4)

    4 - OKYO Pharma Ltd (0001849296) (Issuer)

    9/28/23 6:15:12 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OKYO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by OKYO Pharma Limited

    SCHEDULE 13G - OKYO Pharma Ltd (0001849296) (Subject)

    2/18/26 5:42:07 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by OKYO Pharma Limited

    424B5 - OKYO Pharma Ltd (0001849296) (Filer)

    2/17/26 8:23:41 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by OKYO Pharma Limited

    6-K - OKYO Pharma Ltd (0001849296) (Filer)

    2/13/26 8:59:35 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OKYO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $OKYO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on OKYO Pharma with a new price target

    B. Riley Securities initiated coverage of OKYO Pharma with a rating of Buy and set a new price target of $5.00

    12/8/25 8:35:27 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cerrone Gabriele M acquired $854,308 worth of Ordinary Shares (569,539 units at $1.50) (SEC Form 4)

    4 - OKYO Pharma Ltd (0001849296) (Issuer)

    10/31/23 4:15:10 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brancaccio John P bought $25,005 worth of Ordinary Shares (16,670 units at $1.50) (SEC Form 4)

    4 - OKYO Pharma Ltd (0001849296) (Issuer)

    9/28/23 6:15:12 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OKYO
    Leadership Updates

    Live Leadership Updates

    View All

    OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

    Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company's development program in neuropathic corneal pain (NCP), leveraging urcosimod's FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur

    2/10/26 8:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer

    Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board LONDON and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announces that, effective immediately, Robert J. Dempsey will assume the role of Chief Executive Officer. Gary S. Jacob, Ph.D. will transition to Chief Development Officer and

    1/5/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer

    LONDON and NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Operating Officer. Mr Clementi will formally take up the COO role effective September 1, 2023. Mr. Clementi's extensive experience in the pharmaceutical industry and his achievements make him a valuable addition to the OKYO Pharma team. Dr. Clementi has followed a science-driven career path since completing his NIH Training Fellows

    7/27/23 11:30:30 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OKYO
    Financials

    Live finance-specific insights

    View All

    OKYO Pharma Announces Chairman and Founder Acquires Shares

    LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 24,551 of the Company's ordinary shares on NASDAQ, bringing his total holding to 10,516,297 shares. About Urcosimod (Formerly called OK-101)Urcosimod is a lipid conjugated chemerin peptide agonist

    12/15/25 8:30:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Chairman and Founder Acquires Shares

    LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 27,051 of the Company's ordinary shares on NASDAQ, bringing his total holding to 10,491,746 shares. About Urcosimod (Formerly called OK-101)Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein

    12/3/25 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Chairman and Founder Acquires Shares

    LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 82,018 of the Company's ordinary shares on NASDAQ, bringing his total holding to 10,464,695 shares. About Urcosimod (Formerly called OK-101)Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein c

    11/21/25 8:30:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care